Evidence map›Paper›PMID 24887381›Full record

Trial reportBone marrow transplantation2014

Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances.

X-D Mo, X-Y Zhao, D-H Liu, Y-H Chen, L-P Xu, X-H Zhang, H Chen, W Han, Y Wang, F-R Wang and 3 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

X-D MoPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X-Y ZhaoPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
D-H LiuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Y-H ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
L-P XuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X-H ZhangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
H ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
W HanPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Y WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
F-R WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
J-Z WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
K-Y LiuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X-J Huang1] Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China [2] Peking-Tsinghua Center for Life Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to compare the therapeutic effects of single umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical hematopoietic SCT (haplo-HSCT) in childhood hematologic malignances. We enrolled 410 consecutive children who received either single UCBT (n=37) or haplo-HSCT from a family donor (n=373) during the same time period. For each UCBT recipient, three recipients matched for year of HSCT, underlying diseases, disease status and the length of follow-up were randomly selected from the haplo-HSCT cohort. Hematopoietic recovery was significantly faster in haplo-HSCT recipients than in UCBT recipients. The incidence of chronic GVHD was significantly higher in haplo-HSCT recipients. The incidence of CMV-related interstitial pneumonia was higher in UCBT recipients. The haplo-HSCT recipients had better 1-year OS (73.0% vs 56.8%, P=0.048), lower 1-year non-relapse mortality (NRM, 18.0% vs 35.1%, P=0.026) and lower 2-year NRM rates (19.9% vs 35.1%, P=0.044). The relapse- and disease-free survival rates did not differ significantly between the groups. Our results showed that compared with UCBT, unmanipulated haplo-HSCT can improve the outcomes of children with hematologic malignances.

Indexed as

Cord Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationAdolescentAllograftsChildChild, PreschoolCytomegalovirus InfectionsDisease-Free SurvivalFemaleHematologic NeoplasmsHumansIncidenceLung Diseases, InterstitialMaleSurvival Rate

Identifiers

PMID24887381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.